Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Conference News ACC 2023

Tailored Alerts Up High-Intensity Statin Prescribing: PCDS Statin

Yael L. Maxwell

March 13, 2023

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

News Daily News

Statins Positively Alter Coronary Plaque Composition

Michael O'Riordan

August 23, 2021

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Conference News ACC 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Yael L. Maxwell

March 18, 2017

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Yael L. Maxwell

August 29, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

High Dose Atorvastatin May Prevent Contrast-Induced Kidney Injury in Elective PCI

L.A. McKeown

November 18, 2012

News Daily News

High-dose Statins Reduce CIN in ACS Patients Receiving PCI

Jason Kahn

May 05, 2011

Advertisement

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Tailored Alerts Up High-Intensity Statin Prescribing: PCDS Statin

Heterozygous FH Diagnosed Late, Remains Undertreated

Statins Positively Alter Coronary Plaque Composition

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

High Dose Atorvastatin May Prevent Contrast-Induced Kidney Injury in Elective PCI

High-dose Statins Reduce CIN in ACS Patients Receiving PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content